Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment

• Главные авторы: Yingying Zhang (Автор), Hongxia Duan (Автор), Heming Zhao (Автор), Lingling Qi (Автор), Yanhong Liu (Автор), Zheao Zhang (Автор), Chao Liu (Автор), Liqing Chen (Автор), Mingji Jin (Автор), Youyan Guan (Автор), Zhonggao Gao (Автор), Wei Huang (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2022-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Primary prostate cancer (PC) progresses to castration-resistant PC (CRPC) during androgen deprivation therapy (ADR) in early stages of prostate cancer. Thus, rather than blocking the androgen-related pathway further, docetaxel (DTX)-based therapy has become the most effective and standard first-line...